Rosen Law Firm Encourages uniQure Investors to Meet Deadline

The firm is advising uniQure investors to take action before an upcoming deadline.

Apr. 6, 2026 at 10:10am

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a leading and longstanding legal practice, is encouraging investors in the biopharmaceutical company uniQure N.V. to meet an upcoming deadline related to a class action lawsuit. The firm is advising uniQure investors to take action before this deadline to potentially participate in the case.

Why it matters

uniQure is a prominent gene therapy company, and this class action lawsuit could have significant financial implications for the company and its investors. The Rosen Law Firm's involvement suggests there may be concerns about uniQure's conduct or disclosures that warrant further investigation.

The details

The Rosen Law Firm has set a deadline for uniQure investors to join the class action lawsuit. The firm is encouraging all investors who purchased uniQure securities between a certain date range to contact the firm to potentially participate in the case and recover their losses.

  • The deadline for uniQure investors to join the class action lawsuit is April 5, 2026.

The players

Rosen Law Firm

A leading and longstanding legal practice that specializes in representing investors in class action lawsuits.

uniQure N.V.

A biopharmaceutical company that develops gene therapies for rare and other devastating diseases.

Got photos? Submit your photos here. ›

What’s next

After the April 5th deadline, the Rosen Law Firm will determine the next steps in the class action lawsuit against uniQure.

The takeaway

This class action lawsuit against uniQure highlights the importance for investors to stay informed and take action to protect their financial interests, especially in the complex and rapidly evolving field of gene therapy.